Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
JAMA Ophthalmol. 2014 Jan;132(1):111-4. doi: 10.1001/jamaophthalmol.2013.5819.

Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab.

Author information

  • 1Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington, DC2The Gilbert Family Neurofibromatosis Institute, Children's National Medical Center, Washington, DC3Division of Neurology, Children's National Medical Cente.
  • 2The Brain Tumor Institute, Children's National Medical Center, Washington, DC7Division of Hematology-Oncology, Children's National Medical Center, Washington, DC.
  • 3Division of Hematology-Oncology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.

Abstract

IMPORTANCE:

Children with optic pathway gliomas (OPGs) frequently experience vision loss from their tumors. Standard front-line treatment using carboplatin-based chemotherapy typically produces only a modest benefit (eg, stabilization or 0.2 logMAR improvement) in visual acuity (VA). Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor and acts primarily as an anti-angiogenic agent. Recent reports suggest a qualitative improvement in vision after bevacizumab-based treatment in children with OPGs.

OBSERVATIONS:

We report 4 cases of pediatric OPGs (2 neurofibromatosis type 1-related and 2 sporadic cases) that received treatment with bevacizumab due to progressive VA or visual field (VF) loss despite prior treatment with chemotherapy or proton-beam radiation. All 4 subjects demonstrated a marked improvement in their VA, VF, or both while receiving bevacizumab-based therapy. Three patients had complete resolution of their VA or VF loss in at least 1 eye-2 of whom had previously received bevacizumab therapy.

CONCLUSIONS AND RELEVANCE:

Given that most patients with OPG-related visual impairment will show modest or no visual improvement with standard treatment, the incorporation of bevacizumab in these cases may greatly improve visual outcomes and should be considered in appropriate clinical situations.

PMID:
24232489
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk